Table 1

Demographic data and biomarker concentrations

HIiNPHNon-iNPH disordersADFTLDVADPDMSAPSPCBD
n=54n=82n=295n=50n=19n=75n=70n=34n=34n=15
Female (%)32 (59)29 (35)161 (55)29 (63)14 (74)45 (60)23 (33)20 (59)20 (59)10 (67)
Age; mean (min-max)71 (53–93)73 (52–89)69 (26–88)71 (51–81)69 (55–84)79 (58–88)60 (26–87)65 (49–83)70 (54–82)68 (49–77)
Biomarkers; mean (SD)
T-tau (pg/mL)346 (181)245 (131)496 (443)*** #980 (333)*** ###342 (146)651 (594)*** ##224 (105)315 (200)329 (247)366 (230)
P-tau (pg/mL)50 (20)***32 (12)54 (36)***96 (27)*** ###45 (13)63 (41)***33 (12)35 (18)46 (38)*42 (19)
NFL (pg/mL)1170 (896)1717 (1963)1960 (2508)1977 (3104)2089 (1401)2646 (3475)839 (622)2322 (987)2219 (2761)2137 (1178)
Aβ38 (pg/mL)2181 (645)***1526 (519)2194 (794)***2710 (807)*** ##2324 (608)***2136 (672)***2056 (624)***1888 (856)*2125 (1076)***2091 (684)*
Aβ40 (pg/mL)5425 (1510)***3800 (1193)5428 (1684)***6541 (1654)*** #5801 (1222)***5477 (1540)***5067 (1391)***4650 (1815)*5099 (1965)***5197 (1561)**
Aβ42 (pg/mL)541 (239)***364 (138)454 (197)**#318 (95)###569 (204)***387 (191)###548 (187)***489 (203)*488 (170)*505 (216)
sAPPα (pg/mL)661 (223)***446 (178)693 (282)***865 (310)*** ###738 (279)***631 (262)***715 (262)***597 (209)650 (309)**585 (224)
sAPPβ (pg/mL)508 (166)***321 (121)498 (188)***599 (192)***502 (166)**484 (188)***503 (178)***414 (142)470 (212)**452 (154)
MCP-1 (pg/mL)410 (110)*492 (109)416 (138)**436 (162)400 (101)456 (115)382 (128)**365 (70)**410 (121)448 (272)
  • Number of patients, age and sex in the different neurodegenerative groups and healthy individuals. Sex is presented as n females (%), age as mean and min-max. Significance testing in comparison with iNPH and healthy controls was done by one-way ANCOVA adjusted for age and sex with Dunnett’s multiple comparisons test and shown as *p< 0.05, **p< 0.01, ***p< 0.001 (vs iNPH) and #p< 0.05, ##p< 0.01, ###p< 0.001 (vs healthy controls).

  • Aβ, AD-related amyloid β; AD, Alzheimer’s disease; ANCOVA, analysis of covariance; CBD, corticobasal degeneration; FTLD, frontotemporal lobe degeneration; MCP-1, monocyte chemoattractant protein 1; MSA, multiple system atrophy; NFL, neurofilament light; Non-iNPH disorders, AD+FTLD+VAD+PD+MSA+PSP+CBD; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; P-tau, phosphorylated tau; T-tau, total tau; VAD, vascular dementia; iNPH, idiopathic normal pressure hydrocephalus; sAPP, soluble amyloid precursor protein.